nCOVID-19
E-Workshop
10y
Better.Be.First.
Fast patient
Proof of concept trials

PROOF OF CONCEPT TRIALS

proof of concept trials

ARENSIA delivers high degree of scientific and logistical expertise for Phase I/Ib/IIa and PROOF OF CONCEPT patient studies.

MORE

PHASE I SPECIAL POPULATIONS

phase i special populations

ARENSIA offers exceptional fast recruitment rates for renal and hepatic impaired patients.

MORE

REGULATORY PROCESS

regulatory process

ARENSIA has the know-how to successfully manage the regulatory process in various Eastern European countries.

MORE

Novel Coronavirus (COVID-19) Update

HOME · NEWS · NOVEL CORONAVIRUS (COVID-19) UPDATE

Dear Partners,

Thank you for the continued trust and support!

Our commitment and responsibility towards our patients, employees and partners have never been stronger as we face the COVID-19 pandemic.
We are continuously monitoring the “minute by minute” changes resulting from the outbreak, and are going above and beyond to keep our patients, employees and clinic facilities safe.

As the virus outbreak is rapidly evolving worldwide with major impacts on social life, healthcare systems and the economy, ARENSIA has deployed as of last week an effective business continuity plan (BCP). The plan is available upon request.

All ARENSIA Phase I clinics have implemented the BCP. Key segments of our BCP ensure:

  • Safety for patients and staff during on-site presence (a.o. strict hygiene rules, individual transport for all patients)
  • Patient retention and enrolment
  • Operational continuity in terms of staff, facilities and supply chains

We are preparing for the next level of escalation, to switch as needed from on-site clinic visits to home visits, using a mobile pharmacy/lab service in addition to remote monitoring provisions for our Sponsors.

Having independent ARENSIA Phase I clinics with our own independent, full time staff, located in strategic hospitals in the countries, ensures we have a number of key advantages enabling us to continue operations.

We see no disruptions to the preparations for new studies or regulatory submission dossiers, and will continue to work towards our usual timely efficient start-up activities.

Thank you for your on-going support and co-operation in the good times and now in the more challenging times.
We keep you updated as the situation evolves.

Sincerely Yours,

Dr. Claudia Hesselmann, PhD
Co-founder and Managing Director

16.03.2020
VIDEO INTRO

We use technologies, such as cookies, and process personal data, such as IP addresses and cookie identifiers, to personalise content based on your interests, measure the performance of our content, and derive insights about the audiences who saw it. You can read more about our Cookie Policy here.

I accept I refuse